Clinical trials: Alzheimers Disease, open to volunteers
Alzheimer Disease
[18F]PI-2620 Phase 3 Histopathological Study
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and…
- Trial name
- NCT05641688
- Testing
- [18F]PI-2620
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Lantheus Biosciences Ltd.
Aging
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Background: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities.
- Trial name
- NCT07099053
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer s Disease, Mild Cognitive Impairment
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT07169630
- Testing
- 18F-PF974, 18F-florbetaben
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Dementia, Alzheimer's Type, Alzheimer's Disease
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants.
- Trial name
- TREMHANCE (NCT07688213)
- Testing
- SAR448851
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Alzheimer's Disease
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking.
- Trial name
- NCT07721467
- Testing
- Psilocybin, Cognitive Training
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Dementia, Alzheimer Dementia (AD)
Fuzhou Aging Brain Health Initiative
The goal of this observational study is to learn about the pathophysiological characterization and evolutionary patterns of Alzheimer's disease (AD) in older adults in Fujian Province, China.
- Conditions
- Dementia, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- FAITH (NCT07891429)
- Testing
- Fluids biomarker and neuroimaging of AD diagnosis
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
InRAD Observational Study
The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across…
- Conditions
- Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia
- Trial name
- InRAD (NCT07213700)
- Testing
- None, this is a non-interventional observational study
- Where
- 23 sites in Australia, Austria and 15 more
- Volunteers
- 50,000 people
- Sponsor
- Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
Mild Cognitive Impairment, Alzheimer's Disease
Use of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease
Cognitive decline affects millions of older adults worldwide and has a profound impact on individuals, families, and healthcare systems.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Dementia
- Trial name
- NCT07391436
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Getúlio Vargas University Hospital
Healthy Volunteers, Alzheimer Disease
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Trial name
- NCT07787182
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dementia (Diagnosis), Mild Cognitive Impairment
Choose Myself (Before) Losing Myself
The purpose of this study is to see if an educational interactive booklet about how dementia progresses throughout a person's life can be a helpful tool for patients to think about future decisions that might need to be made…
- Conditions
- Dementia (Diagnosis), Mild Cognitive Impairment, Alzheimer's Disease Dementia, Alzheimer's Disease
- Trial name
- CYOA (NCT07846566)
- Testing
- CYOA booklet
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Cleveland Clinic
Alzheimer's Disease
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants
This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous…
- Trial name
- NCT07889349
- Testing
- SHR 3201 Injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Agitation in Dementia, Including Alzheimer's Disease
Virtual Darkness Theraphy for Agitation in Dementia
Behavioral and psychological symptoms of dementia (BPSD) such as anxiety, depression, psychosis and agitation, are prevalent, often treatment resistant, resource demanding and significantly deteriorates cognition, independency…
- Trial name
- DARKDEM (NCT06451952)
- Testing
- Virtual darkness
- Where
- Norway
- Volunteers
- 72 people
- Sponsor
- University of Bergen
Preclinical Alzheimer's Disease, Alzheimer Disease
AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease.
- Trial name
- AREVIA (NCT07827768)
- Testing
- AV-1959R
- Volunteers
- 160 people
- Sponsor
- Institute for Molecular Medicine
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Amnestic
Deep Brain Stimulation Guided by Brain Mapping to Treat Cognitive Impairment
This trial is a 12-month safety and feasibility study, enrolling up to six participants. These participants will serve as their own controls, structured in multiple parts that follow an initial short-term stereo…
- Conditions
- Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Amnestic, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Memory Deficit
- Trial name
- NCT07887737
- Testing
- Abbott St Jude Medical Infinity™
- Volunteers
- 6 people
- Sponsor
- University of Texas Southwestern Medical Center
Early-Onset Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with…
- Trial name
- NCT05231785
- Testing
- ALN-APP
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD.
- Trial name
- NCT06566170
- Testing
- Donanemab, Usual Care
- Where
- United States
- Volunteers
- 6,250 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
- Trial name
- NCT06875986
- Testing
- Brexpiprazole (Rexulti)
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Early Alzheimer's Disease
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD).
- Trial name
- NCT07033494
- Testing
- MK-2214
- Where
- 80 sites in United States, Argentina and 9 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease and Related Dementias, Alzheimer Disease and Related Dementias
SmartEnLite for Nursing Home Residents With Dementia
The goal of this clinical trial is to learn if the Smart Environmental Lighting (SmartEnLite) can help improve behaviors and sleep among residents with dementia in nursing homes.
- Trial name
- SmartEnLite (NCT07883291)
- Testing
- Smart Environmental Light (SmartEnLite)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Penn State University